Evidence suggests that ACE2 knockout in WTC11C human cardiomyocytes or pretreatment of cardiomyocytes with an ACE2/CTSL inhibitor46 significantly decreases viral presence and apoptosis in the infected cells, flagging ACE2 and CTSL as potential therapeutic targets to prevent COVID‐19 cardiac complications (Figure 2). The gene discussed is CTSL; the disease is COVID-19.